Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Lapatinib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 CNS 1

Conditions

Brain Neoplasms 16 Breast Neoplasms 12 Glioblastoma 5 Neoplasms 3 Gliosarcoma 3 Glioma 3 Ependymoma 3 Oligodendroglioma 2 Neuroma, Acoustic 2 Neurofibromatosis 2 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Central Nervous System Neoplasms 2 Breast Neoplasms, Male 2 Astrocytoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Spinal Cord Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neurilemmoma 1 Medulloblastoma 1 Glioma, Subependymal 1 Familial ependymoma 1 Esophageal Neoplasms 1 Dysgerminoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 23 Bevacizumab 18 Cyclophosphamide 9 Carboplatin 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 5 Filgrastim 5 Radiosurgery 4 Nivolumab 4 Everolimus 4 Etoposide 4 Busulfan 4 sonidegib 3 pembrolizumab 3 olaparib 3 fludarabine phosphate 3 fludarabine 3 antineoplaston AS 2-1 3 antineoplaston A10 3 Vincristine 3 Thiotepa 3 Sirolimus 3 Melphalan 3 IL13-PE38 3 Drug Therapy 3 Antilymphocyte Serum 3 verubulin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00350727 2013-04-19

VEG102857

GlaxoSmithKline

Phase 2 Completed

75 enrolled 45 charts

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡